Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: Press Releases

World Thrombosis Day Leaders Publish Findings from Global VTE Public Awareness Survey

Thursday, June 18, 2015   (0 Comments)
Posted by: Luke Blount
Share |

In a recent public awareness survey by Ipsos-Reid, the ISTH’s World Thrombosis Day initiative found a significant gap in global understanding and awareness of deep vein thrombosis (DVT) and pulmonary embolism (PE), including signs, symptoms, risk factors and causes. Findings point to a need for increased attention and education globally to save lives and prevent and treat VTE. Responses were collected among 800 individuals in Argentina, Australia, Canada, Germany, Japan, Thailand, The Netherlands, United Kingdom and the United States.

View the research online here.

Thrombosis is responsible for one in four deaths worldwide and VTE is a major contributor to this disease burden.

  • In Europe and the U.S., VTE kills more people each year than breast and prostate cancer, motor vehicle crashes and AIDS combined.[i]
  • Up to 60 percent of all VTE cases are hospital-associated and it is the leading preventable cause of hospital death, ahead of infection and pneumonia.[ii]

Despite the incidence of hospital-associated VTE, risk assessments are not universally mandated, resulting in missed opportunities for life-saving prevention.


About World Thrombosis Day

Launched in 2014 and held annually on 13 October, World Thrombosis Day (WTD) aims to increase public, healthcare professional and health care systems’ awareness of thrombosis and, ultimately, to reduce deaths and disabilities from thromboembolic disease through a greater awareness of its causes, risk factors, signs and symptoms, and evidence-based prevention and treatment. WTD’s mission supports the World Health Assembly's global target of reducing premature deaths by non-communicable disease by 25 percent by 2025, as well as the WHO global action plan for the prevention and control of non-communicable diseases in the 2013-2020 timeframe. Unrestricted corporate grants to help support WTD come from founding global partner Bayer HealthCare; global partners are Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer Alliance, Daiichi Sankyo, Medtronic and Portola Pharmaceuticals; and global patron Grifols. Visit for more information.

[i] Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. Thromb Haemost. 2007;98:756-764.

[ii] Jha AK, Larizgoitia I, Audera-Lopez C, Prasopa-Plaisier N, Waters H, Bates DW. The global burden of unsafe medical care: analytic modeling of observational studies. BMJ Qual Saf 2013; 22;809-15.

Membership Management Software Powered by YourMembership  ::  Legal